心肾综合征的最新研究进展。
Updates in Cardiorenal Syndrome.
机构信息
Division of Nephrology, Tufts Medical Center, 800 Washington Street, Box 391, Boston, MA 02111, USA.
Division of Cardiovascular Medicine, Yale School of Medicine, PO Box 208017, New Haven, CT 06520, USA.
出版信息
Med Clin North Am. 2023 Jul;107(4):763-780. doi: 10.1016/j.mcna.2023.03.011. Epub 2023 Apr 15.
Abstract
Cardiorenal syndrome is a term that refers to a collection of disorders involving both the heart and kidneys, encompassing multi-directional pathways between the 2 organs mediated through low arterial perfusion, venous congestion, and neurohormonal activation. The pathophysiology is complex and includes hemodynamic and neurohormonal changes, but inconsistent findings from recent studies suggest this is very heterogenous disorder. Management for ADHF remains focused on decongestion and neurohormonal blockade to overcome the intense sodium and fluid avidity of the CRS.
摘要
心脏肾综合征是一个术语，指的是涉及心脏和肾脏的一系列疾病，包括 2 个器官之间通过低动脉灌注、静脉充血和神经激素激活介导的多向途径。其病理生理学较为复杂，包括血流动力学和神经激素变化，但最近的研究结果不一致，表明这是一种非常异质性的疾病。ADHF 的治疗仍然侧重于充血和神经激素阻断，以克服 CRS 对钠和液体的强烈渴望。
相似文献
1
Updates in Cardiorenal Syndrome.心肾综合征的最新研究进展。
Med Clin North Am. 2023 Jul;107(4):763-780. doi: 10.1016/j.mcna.2023.03.011. Epub 2023 Apr 15.
2
Cardiorenal Syndrome in the Hospital.医院中的心肾综合征。
Clin J Am Soc Nephrol. 2023 Jul 1;18(7):933-945. doi: 10.2215/CJN.0000000000000064. Epub 2023 Jan 13.
3
Cardiorenal syndrome in acute decompensated heart failure.急性失代偿性心力衰竭中的心肾综合征
Expert Rev Cardiovasc Ther. 2012 Feb;10(2):177-89. doi: 10.1586/erc.11.193.
4
Insights into cardiorenal interactions in acute decompensated heart failure.急性失代偿性心力衰竭中心肾相互作用的见解
Curr Opin Cardiol. 2017 Mar;32(2):203-208. doi: 10.1097/HCO.0000000000000378.
5
Cardiorenal syndrome: Decongestion in heart failure across wide spectrum of kidney pathophysiology.心肾综合征：心力衰竭时在广泛的肾脏病理生理范围内的充血解除。
Adv Clin Exp Med. 2022 Apr;31(4):445-455. doi: 10.17219/acem/144327.
6
Heart-Kidney Interactions in Cardiorenal Syndrome Type 1.心肾交互作用在 1 型心肾综合征中的表现。
Adv Chronic Kidney Dis. 2018 Sep;25(5):408-417. doi: 10.1053/j.ackd.2018.08.013.
7
RAAS inhibition and cardiorenal syndrome.肾素-血管紧张素-醛固酮系统抑制与心肾综合征
Curr Hypertens Rev. 2014;10(2):107-11. doi: 10.2174/1573402111666141231144228.
8
Cardiorenal syndrome.心肾综合征
Heart Fail Clin. 2014 Apr;10(2):251-80. doi: 10.1016/j.hfc.2013.12.003. Epub 2014 Feb 4.
9
Safety and Performance of the Aortix Device in Acute Decompensated Heart Failure and Cardiorenal Syndrome.Aortix装置在急性失代偿性心力衰竭和心肾综合征中的安全性与性能
JACC Heart Fail. 2023 Nov;11(11):1565-1575. doi: 10.1016/j.jchf.2023.06.018. Epub 2023 Oct 4.
10
Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network.急性失代偿性心力衰竭的心脏肾脏拯救研究：心力衰竭临床研究网络的 CARRESS-HF 的原理和设计。
J Card Fail. 2012 Mar;18(3):176-82. doi: 10.1016/j.cardfail.2011.12.009. Epub 2012 Feb 2.
引用本文的文献
1
Cardiorenal Syndrome in the Elderly: Challenges and Considerations.老年人心肾综合征：挑战与考量
Geriatrics (Basel). 2025 Aug 4;10(4):104. doi: 10.3390/geriatrics10040104.
2
Acute kidney injury after myocardial infarction: prognostic implications via dual robust methods.心肌梗死后急性肾损伤：通过双重稳健方法的预后意义
Front Med (Lausanne). 2025 Jul 22;12:1555478. doi: 10.3389/fmed.2025.1555478. eCollection 2025.
3
Prognostic value of dynamic KDIGO staging in acute kidney injury after acute heart failure: a doubly robust analysis.急性心力衰竭后急性肾损伤中动态KDIGO分期的预后价值：一项双重稳健分析
Sci Rep. 2025 Jul 2;15(1):22920. doi: 10.1038/s41598-025-07118-y.
4
The association of albumin-corrected anion gap and acute kidney injury in heart failure patients: a competing risk model analysis.心力衰竭患者中白蛋白校正阴离子间隙与急性肾损伤的关联：一项竞争风险模型分析
BMC Cardiovasc Disord. 2025 Apr 11;25(1):277. doi: 10.1186/s12872-025-04723-7.
5
Butyrate-Mediated Modulation of Paraoxonase-1 Alleviates Cardiorenometabolic Abnormalities in a Rat Model of Polycystic Ovarian Syndrome.丁酸盐介导的对氧磷酶-1调节减轻多囊卵巢综合征大鼠模型的心肾代谢异常。
Cardiovasc Drugs Ther. 2024 Nov 16. doi: 10.1007/s10557-024-07649-y.
6
Ubiquitin-Specific Protease 18 in Chronic Kidney Disease-Another Emerging Biomarker to Consider?慢性肾脏病中的泛素特异性蛋白酶18——另一个值得考虑的新兴生物标志物？
Biomedicines. 2024 May 13;12(5):1073. doi: 10.3390/biomedicines12051073.
本文引用的文献
1
Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR.胱抑素 C 在估计肾小球滤过率中的优势、局限性和临床注意事项。
Kidney360. 2022 Aug 23;3(10):1807-1814. doi: 10.34067/KID.0003202022. eCollection 2022 Oct 27.
2
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.联合使用襻利尿剂和噻嗪类利尿剂治疗失代偿性心力衰竭：CLOROTIC试验
Eur Heart J. 2023 Feb 1;44(5):411-421. doi: 10.1093/eurheartj/ehac689.
3
Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.KDIGO 2022 慢性肾脏病糖尿病管理临床实践指南执行摘要：基于快速涌现的新证据的更新。
Kidney Int. 2022 Nov;102(5):990-999. doi: 10.1016/j.kint.2022.06.013.
4
Acetazolamide in Acute Decompensated Heart Failure with Volume Overload.乙酰唑胺治疗急性失代偿性心力衰竭伴容量超负荷
N Engl J Med. 2022 Sep 29;387(13):1185-1195. doi: 10.1056/NEJMoa2203094. Epub 2022 Aug 27.
5
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.用于射血分数降低的心力衰竭伴高钾血症管理的帕替络尔：DIAMOND 试验。
Eur Heart J. 2022 Nov 1;43(41):4362-4373. doi: 10.1093/eurheartj/ehac401.
6
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1.
7
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.钠-葡萄糖协同转运蛋白 2 抑制剂恩格列净治疗急性心力衰竭住院患者的多中心随机试验。
Nat Med. 2022 Mar;28(3):568-574. doi: 10.1038/s41591-021-01659-1. Epub 2022 Feb 28.
8
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure.血管紧张素-脑啡肽酶抑制剂在心力衰竭射血分数谱中的肾脏结局。
Eur J Heart Fail. 2022 Sep;24(9):1591-1598. doi: 10.1002/ejhf.2421. Epub 2022 Jan 18.
9
A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease.一种用于 GFR 估计的统一方法：NKF-ASN 工作组关于重新评估种族在诊断肾脏疾病中的纳入的建议。
J Am Soc Nephrol. 2021 Dec 1;32(12):2994-3015. doi: 10.1681/ASN.2021070988.
10
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.KDIGO 2021肾小球疾病管理指南执行摘要。
Kidney Int. 2021 Oct;100(4):753-779. doi: 10.1016/j.kint.2021.05.015.
Zotero 插件